ABOUT CURIUM
The Group Curium is the world’s largest nuclear medicine company with over 1,2+ B € revenues. At Curium, we have a singular focus – to develop, manufacture and supply world-class radiopharmaceutical products around the globe. With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 15 million patients annually. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service. As a fast-growing company in a niche market, Curium is today owned by a private equity fund with LBO financing scheme.
Building on its unique strengths across radiopharmaceutical product manufacturing, logistics and commercialization, and led by an agile, LBO-driven leadership team, Curium has already achieved a critical mass and is the largest player in the nuclear medicines field. This is one that has become increasingly dynamic and innovative in recent years.
The Director, Global Regulatory Lead (GRL) will provide global regulatory leadership for one or more oncology programs focused on radiopharmaceutical/nuclear medicine therapeutics. This individual will develop and execute innovative global regulatory strategies supporting products from early clinical development through registration and lifecycle management.
The successful candidate will serve as the Global Regulatory Lead for multidisciplinary development teams, partnering closely with Clinical Development, CMC, Nonclinical, Medical, Biostatistics, Quality, Biometrics, and Commercial to accelerate development while ensuring compliance with global regulatory requirements.
The ideal candidate possesses extensive experience across both early- and late-stage drug development, including IND/CTA strategy, global Health Authority interactions, registration planning, and lifecycle management for oncology products. Experience with radiopharmaceuticals is strongly preferred.
Global Regulatory Strategy
Preferred:
Ideal Candidate Profile
The ideal candidate combines deep regulatory expertise with oncology development experience and has successfully led programs from IND/CTA through NDA/BLA or MAA approval. They are comfortable navigating the unique scientific and regulatory challenges associated with targeted radiopharmaceuticals, including dosimetry, isotope manufacturing, companion diagnostics, and accelerated development pathways. They are recognized as a strategic partner capable of influencing senior leadership while effectively collaborating across global, multidisciplinary teams.
ANALYZE + ADAPT
COMMUNICATE EFFECTIVELY
DEVELOP SELF + OTHERS
INTERNAL/EXTERNAL CUSTOMER-FOCUSED
RESULTS-DRIVEN
Curium is the global leader in nuclear medicine, providing life-changing diagnostics and treatment to patients all over the world.
We develop, manufacture and distribute world-class radiopharmaceutical products with a renewed focus on cancer, exploring untapped potential for new innovation.
We build on remarkable foundations and a legacy of providing reliable and consistent nuclear solutions to tens of thousands of patients every day. Our proven heritage combined with a pioneering approach are the hallmarks from which we provide life-changing diagnostics and therapeutics. Our people are the root of the incredible impact they have.
As part of our 2030 vision to become an oncology-focused nuclear medicine leader – both in diagnostics and therapy – we will expand our reach further into Japan and China, continuing to roll out our superior products to a global market. The impact of these investments on patients will be life changing.
Our cancer focus is currently in Neuroendocrine Tumors (NETs) and prostate cancer PSMA. We are also working on leveraging the power of AI to improve image quality and accuracy; to identify patterns to help diagnose pathologies and of course to better support physicians.
Our Promise
We strive to make the impossible possible and to be an organization that will change the face of medicine. Our diverse group of industry experts is unified under one strong and singular focus – to develop, manufacture and supply revolutionary diagnostic and therapeutic radiopharmaceuticals to our customers around the globe with unrivaled reliability and superior service.
